PARNSEPar Drugs and Chemicals Limited· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 16 Sept, 2025 · 16:48 IST

SEBI halts proposed slump sale pending independent valuation

Sebi InvestigationRegulatory & Legal View source PDFExplain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+5.0%Reaction day
₹111.05
prior close
₹116.60
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+4.4% vs market
Pharmaceuticals peers, median of 154sector+0.1%+4.9% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
+0.0
15m
+0.0
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+5.0+0.6+4.4+0.1+4.9
Next day
+7.2+0.4+6.8+0.2+7.0
2d
+1.4+0.8+0.7+0.2+1.3
3d
+1.2+0.0+1.2-0.7+1.9
4d
-1.8-0.3-1.6-0.9-0.9
5d
-0.3-0.6+0.4-1.1+0.8
1w
-6.3-3.8-2.6-4.0-2.3
15d
-7.2-2.9-4.3-3.5-3.7
1m
-9.1-2.9-6.1-3.9-5.2
2m
-15.4-1.5-13.8-4.9-10.5
3m
-11.8-8.1-3.7-8.0-3.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SEBI's 15 September 2025 interim order stopped Par Drugs and Chemicals from proceeding with the 14 February 2025 sale of its business undertaking to Phal-Jig Fine Chemicals. NSE must appoint an independent valuer, and the company must not transfer the related assets until further directions. The company reported no quantified financial or operational impact as of 16 September 2025.

Likely market impact

The proposed sale is on hold, delaying the transaction and creating regulatory uncertainty. The company says there is no quantified financial or operational impact so far.